Is DEHYDRATION a side effect of SORAFENIB (RAF KINASE INHIBITOR) ? ( FactMed.com )

About this FactMed analysis covering adverse side effect reports of SORAFENIB (RAF KINASE INHIBITOR) patients who developed DEHYDRATION.

FactMed provides MD-approved analysis to help both patients, researchers, and physicians accurately assess the risk profile for more than 20,000 different pharmaceutical products. The below report offers compiled information from Food & Drug Administration and FactMed user submissions. Between January 2004 and October 2012, 140 individuals taking SORAFENIB (RAF KINASE INHIBITOR) reported DEHYDRATION to the FDA. A total of 3329 SORAFENIB (RAF KINASE INHIBITOR) drug adverse event reaction reports were made with the FDA during this time period. Often the FDA only receives reports of the most critical and severe cases; these numbers may therefore underrepresent the complication rate of the medication.

FDA Research Report

Introduction This page is designed to help you determine the relationship, if any, between SORAFENIB (RAF KINASE INHIBITOR) and DEHYDRATION. In doing so, we compare SORAFENIB (RAF KINASE INHIBITOR) with other drugs that cause DEHYDRATION, to help you evaluate whether or not SORAFENIB (RAF KINASE INHIBITOR) causes DEHYDRATION. Likewise, this page shows the most highly-reported side effects of SORAFENIB (RAF KINASE INHIBITOR), so you can see if DEHYDRATION ranks among SORAFENIB (RAF KINASE INHIBITOR)'s most well-known side effects.

Summary Statistics
Reports of SORAFENIB (RAF KINASE INHIBITOR) causing DEHYDRATION: 140
Reports of any side effect of SORAFENIB (RAF KINASE INHIBITOR) : 3329
Percentage of SORAFENIB (RAF KINASE INHIBITOR) patients where DEHYDRATION is a reported side effect: 4.2055%

FDA reports of any drug causing DEHYDRATION : 51306
Average percentage for all medicated patients where DEHYDRATION is reported as a complication: 0.3216%

Physician opinion on SORAFENIB (RAF KINASE INHIBITOR) as adverse event culprit:

Overall opinion for all reports of this drug:

Most frequent diagnoses/indications for prescribing SORAFENIB (RAF KINASE INHIBITOR):

HEPATIC NEOPLASM MALIGNANT ( 770 patients )
RENAL CELL CARCINOMA ( 114 patients )
THYROID CANCER ( 65 patients )
METASTATIC RENAL CELL CARCINOMA ( 44 patients )
THYROID CANCER METASTATIC ( 35 patients )
BREAST CANCER ( 31 patients )
BREAST CANCER METASTATIC ( 27 patients )
GASTRIC CANCER ( 25 patients )
NON-SMALL CELL LUNG CANCER ( 25 patients )
COLORECTAL CANCER METASTATIC ( 22 patients )
RENAL CANCER ( 17 patients )
PRODUCT USED FOR UNKNOWN INDICATION ( 14 patients )
BILE DUCT CANCER ( 14 patients )
SALIVARY GLAND CANCER ( 7 patients )
HEPATIC CANCER METASTATIC ( 7 patients )
COLORECTAL CANCER ( 7 patients )
SMALL CELL LUNG CANCER STAGE UNSPECIFIED ( 6 patients )
RECTAL CANCER ( 5 patients )
PANCREATIC CARCINOMA ( 4 patients )
PROSTATE CANCER ( 4 patients )
INTRAOCULAR MELANOMA ( 4 patients )
HEPATIC NEOPLASM MALIGNANT RECURRENT ( 3 patients )
NEOPLASM ( 3 patients )
LIVER DISORDER ( 3 patients )
ANGIOSARCOMA ( 3 patients )
NON-SMALL CELL LUNG CANCER STAGE IV ( 3 patients )
METASTASES TO LUNG ( 3 patients )
HEPATIC NEOPLASM MALIGNANT NON-RESECTABLE ( 3 patients )
COLORECTAL CANCER STAGE IV ( 3 patients )
NEOPLASM MALIGNANT ( 3 patients )
GALLBLADDER CANCER METASTATIC ( 3 patients )
METASTASIS ( 3 patients )
BILIARY CANCER METASTATIC ( 3 patients )
COLON CANCER METASTATIC ( 2 patients )
HYPOPHARYNGEAL CANCER ( 2 patients )
DESMOID TUMOUR ( 2 patients )
NEUROENDOCRINE CARCINOMA ( 2 patients )
LUNG NEOPLASM MALIGNANT ( 2 patients )
ACUTE MYELOID LEUKAEMIA (IN REMISSION) ( 2 patients )
OESOPHAGEAL CARCINOMA ( 2 patients )
METASTATIC MALIGNANT MELANOMA ( 2 patients )
TONGUE NEOPLASM MALIGNANT STAGE UNSPECIFIED ( 2 patients )
METASTATIC SQUAMOUS CELL CARCINOMA ( 2 patients )
RENAL CELL CARCINOMA STAGE IV ( 2 patients )
ANGINA PECTORIS ( 2 patients )
OSTEOSARCOMA METASTATIC ( 2 patients )
METASTATIC OCULAR MELANOMA ( 2 patients )
BONE SARCOMA ( 2 patients )
METASTATIC SALIVARY GLAND CANCER ( 2 patients )
TONSIL CANCER ( 2 patients )
MYELODYSPLASTIC SYNDROME ( 1 patients )
PROSTATE CANCER METASTATIC ( 1 patients )
GALLBLADDER CANCER ( 1 patients )
NEUROENDOCRINE TUMOUR ( 1 patients )
MALIGNANT NEOPLASM OF RENAL PELVIS ( 1 patients )
GLIOMA ( 1 patients )
BLADDER CANCER ( 1 patients )
OVARIAN CANCER METASTATIC ( 1 patients )
CAROTID ARTERY DISEASE ( 1 patients )
HEPATOBLASTOMA ( 1 patients )
NASOPHARYNGEAL CANCER ( 1 patients )
LUNG ADENOCARCINOMA ( 1 patients )
RENAL CANCER METASTATIC ( 1 patients )
ACUTE MYELOID LEUKAEMIA ( 1 patients )
DIFFUSE LARGE B-CELL LYMPHOMA ( 1 patients )
NEUROENDOCRINE CARCINOMA OF THE SKIN ( 1 patients )
MALIGNANT HISTIOCYTOSIS ( 1 patients )
MALIGNANT SOFT TISSUE NEOPLASM ( 1 patients )
SARCOMA ( 1 patients )
ANTICOAGULANT THERAPY ( 1 patients )
GERM CELL CANCER ( 1 patients )
OESOPHAGEAL ADENOCARCINOMA ( 1 patients )
SQUAMOUS CELL CARCINOMA ( 1 patients )
HEAD AND NECK CANCER ( 1 patients )
OVARIAN EPITHELIAL CANCER ( 1 patients )
( 0 patients )

Drugs with high FDA adverse event association with DEHYDRATION:

ASPIRIN (4930 patients)
LASIX (2777 patients)
FOSAMAX (2721 patients)
CISPLATIN (2627 patients)
LISINOPRIL (2455 patients)
PREDNISONE (2354 patients)
FUROSEMIDE (2149 patients)
AVONEX (1976 patients)
OMEPRAZOLE (1955 patients)
DEXAMETHASONE (1940 patients)
VIOXX (1899 patients)
LIPITOR (1863 patients)
ZOMETA (1861 patients)
CARBOPLATIN (1841 patients)
FLUOROURACIL (1836 patients)
ZOFRAN (1765 patients)
NEXIUM (1763 patients)
COUMADIN (1666 patients)
FOLIC ACID (1637 patients)
ACETAMINOPHEN (1576 patients)
HEPARIN SODIUM INJECTION (1574 patients)
ATENOLOL (1559 patients)
SEROQUEL (1554 patients)
DIGOXIN (1534 patients)
SYNTHROID (1534 patients)
HYDROCHLOROTHIAZIDE (1517 patients)
SIMVASTATIN (1475 patients)
POTASSIUM CHLORIDE (1419 patients)
PROTONIX (1403 patients)
PRILOSEC (1374 patients)
RIBAVIRIN (1362 patients)
FORTEO (1351 patients)
HUMIRA (1329 patients)
ALLOPURINOL (1319 patients)
METFORMIN HCL (1317 patients)
REVLIMID (1310 patients)
NEURONTIN (1291 patients)
XANAX (1270 patients)
AMBIEN (1269 patients)
PLAVIX (1262 patients)
OXYCONTIN (1260 patients)
REMICADE (1234 patients)
NORVASC (1231 patients)
LEVOTHYROXINE SODIUM (1228 patients)
COMPAZINE (1220 patients)
LORAZEPAM (1218 patients)
ATIVAN (1218 patients)
ZOLOFT (1176 patients)
ZOCOR (1173 patients)
PEG-INTRON (1164 patients)
OXALIPLATIN (1098 patients)
DECADRON (1088 patients)
IBUPROFEN (1063 patients)
CAPECITABINE (1060 patients)
ACCUTANE (1059 patients)
LANTUS (1015 patients)
ALBUTEROL (1004 patients)
TOPROL-XL (1000 patients)
PREDNISOLONE (989 patients)
VITAMIN D (976 patients)
LEXAPRO (973 patients)
PREVACID (972 patients)
SPIRONOLACTONE (956 patients)
METHOTREXATE (955 patients)
XELODA (947 patients)
DIANEAL (943 patients)
AVASTIN (939 patients)
METOPROLOL TARTRATE (936 patients)
PACLITAXEL (926 patients)
BEVACIZUMAB (926 patients)
PERCOCET (923 patients)
PREDNISONE TAB (922 patients)
CETUXIMAB (897 patients)
MORPHINE (893 patients)
OXYCODONE HCL (889 patients)
LYRICA (879 patients)
VICODIN (876 patients)
DIOVAN (870 patients)
BYETTA (861 patients)
AREDIA (836 patients)
LEVAQUIN (835 patients)
DOCETAXEL (809 patients)
CELEBREX (809 patients)
TAXOL (805 patients)
AMLODIPINE (803 patients)
TYSABRI (789 patients)
RADIATION THERAPY (787 patients)
WARFARIN SODIUM (777 patients)
GABAPENTIN (777 patients)
CALCIUM (775 patients)
DURAGESIC-100 (774 patients)
CYMBALTA (769 patients)
ALDACTONE (765 patients)
MULTI-VITAMINS (762 patients)
CYCLOPHOSPHAMIDE (756 patients)
VELCADE (749 patients)
COREG (740 patients)
TAXOTERE (734 patients)
INSULIN (725 patients)
PAXIL (722 patients)
RAMIPRIL (719 patients)
ONDANSETRON (716 patients)
METOCLOPRAMIDE (710 patients)
CRESTOR (708 patients)
FENTANYL (705 patients)
VITAMIN B-12 (701 patients)
ALPRAZOLAM (695 patients)
EXJADE (682 patients)
LEUCOVORIN CALCIUM (680 patients)
IMODIUM (656 patients)
ENALAPRIL MALEATE (653 patients)
TRAMADOL HCL (643 patients)
MULTI-VITAMIN (642 patients)
LANSOPRAZOLE (641 patients)
GLUCOPHAGE (641 patients)
ZYPREXA (640 patients)
PEGASYS (633 patients)
METOPROLOL (633 patients)
EFFEXOR (626 patients)
MORPHINE SULFATE (626 patients)
BENADRYL (621 patients)
REGLAN (614 patients)
SUTENT (603 patients)
LORTAB (598 patients)
ZANTAC (598 patients)
LOVENOX (596 patients)
CLONAZEPAM (595 patients)
COLACE (593 patients)
ADVAIR DISKUS 100/50 (589 patients)
CIPROFLOXACIN (587 patients)
NITROGLYCERIN (586 patients)
DILAUDID (584 patients)
FLUCONAZOLE (582 patients)
ALTACE (579 patients)
MEGACE (577 patients)
ARANESP (575 patients)
RISPERDAL (569 patients)
PROZAC (548 patients)
BACTRIM (545 patients)
RANITIDINE (537 patients)
ACYCLOVIR (534 patients)
LOPRESSOR (533 patients)
SANDOSTATIN LAR (530 patients)
IRINOTECAN HCL (530 patients)
ENBREL (526 patients)
LOMOTIL (526 patients)
COZAAR (526 patients)
REBIF (525 patients)
PREMARIN (522 patients)
TRAZODONE HCL (517 patients)
SPIRIVA (517 patients)
ERBITUX (515 patients)
DOXORUBICIN HCL (515 patients)
NEXAVAR (513 patients)
METFORMIN (509 patients)
CALCIUM CARBONATE (507 patients)
FLOMAX (505 patients)
PEPCID (502 patients)
CELEXA (500 patients)
TYLENOL (499 patients)
FERROUS SULFATE TAB (496 patients)
PANTOPRAZOLE (494 patients)
AMOXICILLIN (488 patients)
ACTOS (482 patients)
REBETOL (481 patients)
WELLBUTRIN (478 patients)
FAMOTIDINE (474 patients)
NYSTATIN (473 patients)
GLYBURIDE (472 patients)
NOVOLOG (460 patients)
ASCORBIC ACID (458 patients)
CARVEDILOL (454 patients)
SINGULAIR (453 patients)
VINCRISTINE (453 patients)
PROMETHAZINE (453 patients)
NEUPOGEN (452 patients)
MIRALAX (451 patients)
LACTULOSE (451 patients)
HUMALOG (449 patients)
GLIPIZIDE (449 patients)
AMITRIPTYLINE HCL (443 patients)
MS CONTIN (443 patients)
PHENERGAN (442 patients)
VALIUM (441 patients)
PROCHLORPERAZINE (433 patients)
MYCOPHENOLATE MOFETIL (432 patients)
MAGNESIUM OXIDE (431 patients)
PANITUMUMAB (430 patients)
IRON (429 patients)
CIPRO (422 patients)
LAPATINIB (421 patients)
EXELON (419 patients)
METOPROLOL SUCCINATE (416 patients)
ALLEGRA (414 patients)
DIFLUCAN (411 patients)
CYCLOSPORINE (411 patients)
FLEXERIL (410 patients)
ACTONEL (407 patients)
TYLENOL (CAPLET) (407 patients)
DIAZEPAM (406 patients)
ZYRTEC (405 patients)
SORAFENIB (398 patients)
CLOZARIL (396 patients)
KLONOPIN (393 patients)
PANTOPRAZOLE SODIUM (393 patients)
GEMCITABINE (392 patients)
ARICEPT (388 patients)
SODIUM CHLORIDE (385 patients)
DEXAMETHASONE TAB (384 patients)
CLONIDINE (383 patients)

Most common side effects for patients taking SORAFENIB (RAF KINASE INHIBITOR):

DIARRHOEA (613 patients)
HEPATIC FAILURE (378 patients)
PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME (342 patients)
HEPATIC ENCEPHALOPATHY (320 patients)
FATIGUE (300 patients)
RASH (276 patients)
ASCITES (253 patients)
ABDOMINAL PAIN (237 patients)
DECREASED APPETITE (226 patients)
UPPER GASTROINTESTINAL HAEMORRHAGE (198 patients)
PYREXIA (191 patients)
ASPARTATE AMINOTRANSFERASE INCREASED (179 patients)
NAUSEA (165 patients)
HYPERTENSION (160 patients)
ASTHENIA (154 patients)
DEHYDRATION (140 patients)
HEPATIC FUNCTION ABNORMAL (133 patients)
DYSPNOEA (131 patients)
CONFUSIONAL STATE (131 patients)
HYPOKALAEMIA (125 patients)
ALOPECIA (124 patients)
VOMITING (118 patients)
CONSTIPATION (115 patients)
INTERSTITIAL LUNG DISEASE (114 patients)
LEFT VENTRICULAR DYSFUNCTION (113 patients)
DEATH (113 patients)
ENDOCARDITIS (112 patients)
ARTHRALGIA (111 patients)
STOMATITIS (111 patients)
ABDOMINAL PAIN UPPER (110 patients)
JAUNDICE (108 patients)
HEPATIC NEOPLASM MALIGNANT (106 patients)
GASTROINTESTINAL HAEMORRHAGE (106 patients)
RETINAL VASCULAR THROMBOSIS (103 patients)
LOWER GASTROINTESTINAL HAEMORRHAGE (103 patients)
LIVER CARCINOMA RUPTURED (101 patients)
OEDEMA PERIPHERAL (97 patients)
PLEURAL EFFUSION (97 patients)
STAPHYLOCOCCAL INFECTION (96 patients)
PNEUMONIA BACTERIAL (96 patients)
ENTEROBACTER INFECTION (96 patients)
MYOPATHY (95 patients)
DRY MOUTH (94 patients)
PAIN IN EXTREMITY (93 patients)
ANXIETY (90 patients)
MALAISE (89 patients)
PULMONARY EMBOLISM (85 patients)
ANAEMIA (84 patients)
PLATELET COUNT DECREASED (81 patients)
BACK PAIN (79 patients)
SEPSIS (78 patients)
PRURITUS (78 patients)
DUODENAL ULCER (77 patients)
MIGRAINE (76 patients)
MITRAL VALVE INCOMPETENCE (76 patients)
HYPOGLYCAEMIA (76 patients)
C-REACTIVE PROTEIN INCREASED (74 patients)
BLOOD PRESSURE INCREASED (73 patients)
VARICES OESOPHAGEAL (73 patients)
HEADACHE (72 patients)
RETINAL VEIN OCCLUSION (72 patients)
ABASIA (69 patients)
RENAL FAILURE ACUTE (69 patients)
WEIGHT DECREASED (67 patients)
DEEP VEIN THROMBOSIS (67 patients)
DIZZINESS (65 patients)
ERYTHEMA (65 patients)
GENERAL PHYSICAL HEALTH DETERIORATION (64 patients)
CONVULSION (63 patients)
ALANINE AMINOTRANSFERASE INCREASED (62 patients)
DYSPHONIA (62 patients)
CEREBRAL HAEMORRHAGE (60 patients)
APHAGIA (58 patients)
COLITIS (58 patients)
PNEUMONIA (57 patients)
GASTRIC ULCER (56 patients)
HYPONATRAEMIA (55 patients)
HAEMOGLOBIN DECREASED (53 patients)
RESPIRATORY FAILURE (52 patients)
LUNG DISORDER (52 patients)
CEREBRAL ISCHAEMIA (49 patients)
PARAESTHESIA (49 patients)
BLOOD BILIRUBIN INCREASED (48 patients)
GAIT DISTURBANCE (48 patients)
THYROID CANCER METASTATIC (44 patients)
DEPRESSED LEVEL OF CONSCIOUSNESS (43 patients)
PERICARDIAL EFFUSION (41 patients)
THROMBOCYTOPENIA (41 patients)
BLISTER (41 patients)
FEBRILE NEUTROPENIA (40 patients)
BLOOD LACTATE DEHYDROGENASE INCREASED (40 patients)
HALLUCINATION (40 patients)
CHILLS (40 patients)
AMMONIA INCREASED (39 patients)
SKIN ULCER (39 patients)
BLOOD ALKALINE PHOSPHATASE INCREASED (38 patients)
PAIN (38 patients)
HYPOALBUMINAEMIA (38 patients)
HYPOCALCAEMIA (37 patients)
FALL (37 patients)
POLLAKIURIA (37 patients)
BLOOD PRESSURE DECREASED (37 patients)
SKIN EXFOLIATION (37 patients)
INSOMNIA (36 patients)
CARDIAC ARREST (36 patients)
HYPOAESTHESIA (35 patients)
INFECTIOUS PERITONITIS (35 patients)
MYOCARDIAL INFARCTION (35 patients)
RETINAL VASCULAR DISORDER (34 patients)
RENAL FAILURE (34 patients)
LIPASE INCREASED (34 patients)
HYPERKALAEMIA (33 patients)
HYPERGLYCAEMIA (33 patients)
HAEMOPTYSIS (31 patients)
ATRIAL FIBRILLATION (30 patients)
GENERALISED OEDEMA (30 patients)
FAECAL INCONTINENCE (30 patients)
WHITE BLOOD CELL COUNT DECREASED (30 patients)
CELLULITIS (29 patients)
CHEST PAIN (29 patients)
SOMNOLENCE (29 patients)
HYPERBILIRUBINAEMIA (28 patients)
HYPOTENSION (28 patients)
MUSCLE SPASMS (28 patients)
ABDOMINAL DISTENSION (27 patients)
WHITE BLOOD CELL COUNT INCREASED (27 patients)
VISION BLURRED (27 patients)
HEPATIC PAIN (26 patients)
BLOOD ALBUMIN DECREASED (26 patients)
DYSURIA (25 patients)
RASH GENERALISED (25 patients)
BLOOD SODIUM DECREASED (25 patients)
BLOOD URIC ACID INCREASED (25 patients)
COMA (25 patients)
COUGH (25 patients)
PANCYTOPENIA (25 patients)
ACUTE ABDOMEN (24 patients)
EOSINOPHIL COUNT INCREASED (24 patients)
CEREBROVASCULAR ACCIDENT (24 patients)
METASTASES TO CENTRAL NERVOUS SYSTEM (23 patients)
CEREBRAL INFARCTION (23 patients)
HYPOMAGNESAEMIA (23 patients)
RETINAL VEIN THROMBOSIS (23 patients)
GAMMA-GLUTAMYLTRANSFERASE INCREASED (23 patients)
TUMOUR LYSIS SYNDROME (22 patients)
HYPOPHOSPHATAEMIA (22 patients)
INFECTION (22 patients)
ORAL PAIN (22 patients)
BLOOD CREATININE INCREASED (22 patients)
NEUTROPENIA (22 patients)
RENAL IMPAIRMENT (22 patients)
LETHARGY (22 patients)
SKIN TOXICITY (21 patients)
TONGUE BLISTERING (21 patients)
LIVER ABSCESS (21 patients)
HAEMATEMESIS (21 patients)
OESOPHAGEAL VARICES HAEMORRHAGE (20 patients)
MENTAL IMPAIRMENT (20 patients)
NERVOUSNESS (20 patients)
NEPHROTIC SYNDROME (20 patients)
HYPOPHAGIA (20 patients)
ADRENAL INSUFFICIENCY (19 patients)
DRY SKIN (19 patients)
BLOOD AMYLASE INCREASED (19 patients)
OEDEMA (19 patients)
INFECTIOUS PLEURAL EFFUSION (19 patients)
DYSPEPSIA (19 patients)
COMA HEPATIC (19 patients)
HEART RATE INCREASED (18 patients)
HYPERTENSIVE CRISIS (18 patients)
MYALGIA (18 patients)
ECZEMA (18 patients)
URINARY TRACT INFECTION (18 patients)
NEUROMYOPATHY (18 patients)
MEDICAL DEVICE COMPLICATION (18 patients)
DIVERTICULITIS (18 patients)
OSTEOMYELITIS (18 patients)
CEREBRAL ATROPHY (18 patients)
CEREBRAL VENTRICLE DILATATION (18 patients)
DIABETIC FOOT INFECTION (18 patients)
NECK PAIN (18 patients)
OLIGURIA (17 patients)
GASTROINTESTINAL DISORDER (17 patients)
HAEMATOCHEZIA (17 patients)
DISSEMINATED INTRAVASCULAR COAGULATION (17 patients)
HYPOTHYROIDISM (17 patients)
TRANSAMINASES INCREASED (17 patients)
OROPHARYNGEAL PAIN (17 patients)
CHRONIC MYELOID LEUKAEMIA (17 patients)
NEOPLASM PROGRESSION (17 patients)
METASTASES TO ADRENALS (16 patients)
LYMPHOCYTE COUNT DECREASED (16 patients)
INTERNATIONAL NORMALISED RATIO INCREASED (16 patients)
MULTI-ORGAN FAILURE (16 patients)
FEAR (16 patients)
PANCREATIC CARCINOMA (16 patients)
HYPERSOMNIA (16 patients)
EPILEPSY (16 patients)
SUBARACHNOID HAEMORRHAGE (16 patients)
METASTASES TO LUNG (16 patients)
TACHYCARDIA (16 patients)
MUSCULAR WEAKNESS (16 patients)
KLEBSIELLA SEPSIS (16 patients)
MYOCARDIAL ISCHAEMIA (16 patients)
DYSGEUSIA (16 patients)
LUNG INFECTION (16 patients)
FAECES DISCOLOURED (16 patients)
PAIN OF SKIN (16 patients)
SPINAL FRACTURE (16 patients)
PANIC REACTION (16 patients)

In addition to reviewing our up-to-date FDA research, users may interact with the FactMed community - currently one million members and growing! FactMed online research and discussions are read by patients, scientists, physicians, and other interested health care parties. Post follow up Questions to learn from our diverse readership. Likewise, patients who have experienced unwanted effects are encouraged to share their Concerns to help educate and inform our members.

Recent FactMed Activity for SORAFENIB (RAF KINASE INHIBITOR)

Issue	Description / Topic	Timestamp

My Patient Resources

Get your questions answered! Over one million patients, researchers, and health care providers have visited FactMed. If you have a question about DEHYDRATION and SORAFENIB (RAF KINASE INHIBITOR), post it here. You may receive a response from a fellow patient - or a leading expert in the field.

Your Question:

Share your experience: Over one million patients, researchers, and health care providers have visited FactMed. If you have a noteworthy experience as a patient taking SORAFENIB (RAF KINASE INHIBITOR), post it here. Your story could help a fellow patient - or provide insight to a leading expert in the field.

Your Experience or Concern:

Telemedicine Expert Consults FactMed newest feature allows patients to consult - via realtime videoconferencing - experts in SORAFENIB (RAF KINASE INHIBITOR). This premium feature connects patients to experts, regardless of geography. FactMed experts charge reasonable rates that may be reimbursable by your insurance as a second-opinion.

We are currently accepting registration for SORAFENIB (RAF KINASE INHIBITOR) experts. If you are a healthcare provider experienced in prescribing SORAFENIB (RAF KINASE INHIBITOR), please register here.